1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH search results confirm RFA-AI-22-028 is listed as 'Expired' and the stored deadline of 2025-02-28 aligns with the expiration. The URL returned 403 but the grant's expired status is confirmed via NIH search index.
Partnerships for Development of Innovative Therapeutics for Select Bacterial and Fungal Pathogens (R01) is sponsored by National Institutes of Health (NIAID). Encourages public-private partnerships to develop interventions against AMR pathogens. While therapy-focused, it supports genomic research to understand resistance mechanisms in global priority pathogens.
Get alerted about grants like this
Get emailed when new opportunities from “National Institutes of Health (NIAID)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, Nonprofits, and For-profit organizations. Confirm the full requirements in the official notice before applying.
The published deadline was February 28, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Partnerships for Development of Innovative Therapeutics for Select Bacterial and Fungal Pathogens (R01) is funded by National Institutes of Health (NIAID). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start with the full solicitation document linked on this page — it contains the submission instructions and required forms.
After a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read articleNIH's FY2026 budget held steady at $47.2 billion — yet by the end of February the agency had issued roughly 66% fewer competitive grant awards than its FY21–24 average, and by late spring award volume was still running dramatically below historical norms. The cause is not a budget cut. It is a pipeline failure: only 14 Notices of Funding Opportunity published by mid-March versus 756 in all of 2024, a workforce down nearly 20%, funds held by OMB into March, and new political-appointee sign-off on NOFOs. FY25 success rates fell to 17% — the lowest in 30 years — and early-stage investigators dropped to 18.5%. This is the definitive breakdown of what is happening, why the money isn't moving, and the concrete diversification strategy labs need for the next 18 months.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read article